PRELIMINARY PROGRAM SSHNO 2026
THURSDAY 17TH September
08.00 Coffee and registration
08.30 WELCOME - President SSHNO Åse Bratland, President NSHNO Arild Østhus
PROTON THERAPY IN HEAD AND NECK - Chair: Jesper Grau Eriksen and Marianne Brydøy
08.45 - 09.30 Proton therapy in Head and Neck, S. J. Frank
09.30 - 09.40 Dahanca 35 - too late to the party? J. Friborg
09.40 - 09.50 Artscan V, radiotherapy with photons vs protons in early tonsil cancer, M. Gebre-Medihn
09.50 - 10.00 PRORADNOR - investigating protons vs photons in Norwegian head and neck cancer patients, H. A. Eide
10.00 - 10.30 Torpedo trial: a phase III randomised controlled trial of proton beam therapy for oropharyngeal cancer, J. Price
10.30 - 11.00 Panel: future in proton beam therapy in Head and neck cancer, C. Grau, J. Price and S. J. Frank
11.00 - 11.20 Coffee break
GOOD PROGNOSIS HEAD AND NECK CANCER - Chair: Maria Gebre-Medhin
11.20 - 11.40 Epidemiology: HPV in Norway/the Nordics, T. Falkenthal
11.40 - 12.00 Positive PET-CT, Negative cfHPV-DNA – Which Should We Trust? The Stockholm Experience M. Zupancic
12.00 - 12.20 The Nordic Oropharyngeal Cancer Cohort: First results, J. Hansen
12.20 - 13.10 LUNCH
ORAL PRESENTATIONS - Chair: Kristine Bjørndal and Cecilie Delphin Amdal
13.10 - 13.20 Prognostic Biomarkers for Treatment of Head and Neck Squamous Cell Carcinoma with Pembrolizumab or Nivolumab,
13.20 - 13.30 Circulating HPV-DNA in detection of residual disease and recurrence in HPV+ OPSCC: The DAHANCA 42 study,
13.30 - 13.40 Radiotherapy for High-Risk Non-Melanoma Skin Cancer of the Head and Neck: A Ten- Year Institutional Experience,
13.40 - 13.50 Cosmetic Outcomes After Radiotherapy for Cutaneous Squamous Cell Carcinoma: A Danish Prospective Study,
13.50 - 14.00 Hypofractionated Radiotherapy of Localized Basal Cell Carcinomas – A randomised trial, Anita Wahlstrøm Olsen
14.00 - 14.25 Coffee break
HIGH RISK NON-MELANOMA SKIN CANCER – NEW TREATMENT APPROACHES - Chair: Thorsteinn Astradsson
14.25 - 14.45 High risk non-melanoma skin cancer – beyond PD-1 blocking, S. Livanainen
14.45 - 15.05 High-risk features and histological resection margins: A pathologist’s perspective, K. H. Liland
15.05 - 15.25 Surgery, M. von Beckerath
15.30 - 16.25 Case presentations and discussion, H. Stenwig-Li
16.30 - 17.00 GENERAL ASSEMBLY
17.50 - 20.00 GET TOGETHER - Oslo City Hall
Mahmoud Bazina
Simone Kloch Bendtsen
Marie Søfteland Sandvei
Helene Borup Larsen
FRIDAY 18TH September
ROBOTIC SURGERY - Chair: Bjørn Palmgren
08.30 - 09.00 Tannlege Aase og Frues invited lecture; From Innovation to Standard of Care: The Trajectory of TORS in Head
09.00 - 09.20 HPV-Positive OPSCC in Denmark: Changing Epidemiology and status on QoLATI/DAHANCA 34 trial,
09.20 - 09.40 TORS, Status in Norway, O. Rikardsen
ORAL PRESENTATIONS - Chair: Vaka Yr Sævarsdottir and Henry Blomster
09.45 - 09.55 Compliance to national guidelines in HNSCC node-positive patients treated with radiotherapy
09.55 - 10.05 Long term oral health problems in head and neck cancer survivors, a multinational cross-sectional study,
10.05 - 10.15 Learning to live with a stoma: Patients’ and nurses’ experiences of education after laryngectomy,
10.15 - 10.25 Clinical Outcomes after FDG-PET-Guided Dose painting in Poor-Prognosis Head and Neck Cancer,
10.25 - 10.55 Coffee break
POOR PROGNOSIS HNSCC - Chair: Hanne Tøndel
11.00 - 11.30 How should we apply the data from KEYNOTE-689 and NIVOPOST-OP in real-world clinical practice? K. Harrington
11.30 - 12.00 Shaping the future of salvage surgery in recurrent head and neck cancer, V. Paleri
12.00 - 12.15 RADPAINT-study, E. Dale
12.15 - 12.30 Palliative care, K. Skedsmo
12.30 - 13.15 LUNCH
ORAL PRESENTATIONS - Chair: Maria Gebre-Medhin and Borghild Ljøkjel
13.20 - 13.30 Incidence and survival of supraglottic squamous cell carcinoma, 1986–2020: a Danish population-based DAHANCA study
13.30 - 13.40 Impact of an intraoral stent on Dosimetry and Patient‑Reported Outcomes in Head and Neck Radiotherapy
13.40 - 13.50 Unilateral radiotherapy of lateralized oral cavity and pharynx squamous cell carcinomas, Jesper Grau Eriksen
13.50 - 14.05 SSHNO travel grant winner, Øyvind Vesterfjell
14.05 - 14.30 Coffee break
FOLLOW-UP
14.30 - 14.50 Follow-up of HNC patients, introduction, P. Koivunen
14.50 - 15.25 Presentation from the Scandinavian countries:
15.25 - 15.55 Panel discussion – future perspectives on follow-up
15.55 - 16.05 SSHNO price winners
Next SSHNO Iceland 2028
16.05 - 16.15 Adjourn
C. von Buchwald
and Neck Oncology, V. Paleri
Torunn Mittet and Karoline Skedsmo
and weekly cisplatin,
Kristine Løken Westgaard
Markus Bækkedal Sonnenberg
Janne Minet Pedersen
Øyvind Vesterfjell
Sweden, B. Palmgren
Finland, P. Koivunen
Denmark, K. Bjørnland
Iceland, T. Astradsson
Norway, E. Kvestad
Emilie Helene Kledal Overgaard
Registration
SSHNO
©2026 by Vidar Petterson Design